VarmX

New appointment in the VarmX leadership team: We're pleased to announce that Martijn Negen has been appointed COO of VarmX. Having supported us as SVP Global Commercial Strategy & Business Development since last September, he is now stepping up to the COO role.   Jan Øhrstrøm, Chairman of VarmX, commented: “Martijn’s appointment further strengthens our ability to navigate the exciting and challenging next phase of growth, as we raise a Series C funding round and drive forward a pivotal Phase 3 trial."    See the news here: https://lnkd.in/dBFM3JrU #management #appointment #lifesciences #innovation

VarmX Presents New Data at ISTH 2024     Leiden, The Netherlands, 26 June 2024 – VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, this week presented new data at the 2024 International Society on Thrombosis and Haemostasis (ISTH) Congress, in Bangkok, Thailand.   VarmX was selected by the conference organisers for an oral presentation on the effectiveness of the Company’s lead asset, VMX-C001, in preventing rivaroxaban-induced bleeding in a liver injury model.   VMX-C001 is a modified recombinant human factor X (FX). It is in clinical development for the treatment of severe spontaneous bleeding and the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy.   The data presented by Daniël Verhoef, VarmX’s Director of Research, show that VMX-C001 completely reversed the increase in bleeding time and blood loss induced by treatment with DOAC rivaroxaban in a liver injury model.   Commenting on the new data, Dr. Jan Öhrström, Chairman of VarmX, said: “We are excited to share this new data from a bleeding model confirming that VMX-C001 rapidly restores coagulation in the presence of FXa blood clotting inhibitors. Currently there are very limited treatment options for patients on blood thinning DOACs that suffer severe bleeding or require urgent surgery, making this an important development for patients and physicians across the globe.”   VarmX intends to publish this data in a peer reviewed journal later this year. For further information on the study and results, please contact: info@varmx.com.   About VarmX VarmX is a spin-off from the Leiden University Medical Center (LUMC), founded in 2016 by Professor Pieter Reitsma, a world leading expert in hemostasis and thrombosis. VarmX’s lead compound VMX-C001 is a modified recombinant blood factor X. The compound is being developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The Company is supported by a strong syndicate of investors including Sound Bioventures, EIC, EQT Life Sciences (formerly LSP), Inkef, Lundbeckfonden BioCapital, Ysios Capital, BioGeneration Ventures and InnovationQuarter.   For further information, please contact:   Instinctif Partners (media enquiries) Melanie Toyne-Sewell / Katie Duffell Tel: +44 20 7457 2020 Email: VarmX@instinctif.com

VarmX Presents New Data at ISTH 2024     Leiden, The Netherlands, 26 June 2024 – VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, this week presented new data at the 2024 International Society on Thrombosis and Haemostasis (ISTH) Congress, in Bangkok, Thailand.   VarmX was selected by the conference organisers for an oral presentation on the effectiveness of the Company’s lead asset, VMX-C001, in preventing rivaroxaban-induced bleeding in a liver injury model.   VMX-C001 is a modified recombinant human factor X (FX). It is in clinical development for the treatment of severe spontaneous bleeding and the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy.   The data presented by Daniël Verhoef, VarmX’s Director of Research, show that VMX-C001 completely reversed the increase in bleeding time and blood loss induced by treatment with DOAC rivaroxaban in a liver injury model.   Commenting on the new data, Dr. Jan Öhrström, Chairman of VarmX, said: “We are excited to share this new data from a bleeding model confirming that VMX-C001 rapidly restores coagulation in the presence of FXa blood clotting inhibitors. Currently there are very limited treatment options for patients on blood thinning DOACs that suffer severe bleeding or require urgent surgery, making this an important development for patients and physicians across the globe.”   VarmX intends to publish this data in a peer reviewed journal later this year. For further information on the study and results, please contact: info@varmx.com.   About VarmX VarmX is a spin-off from the Leiden University Medical Center (LUMC), founded in 2016 by Professor Pieter Reitsma, a world leading expert in hemostasis and thrombosis. VarmX’s lead compound VMX-C001 is a modified recombinant blood factor X. The compound is being developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The Company is supported by a strong syndicate of investors including Sound Bioventures, EIC, EQT Life Sciences (formerly LSP), Inkef, Lundbeckfonden BioCapital, Ysios Capital, BioGeneration Ventures and InnovationQuarter.   For further information, please contact:   Instinctif Partners (media enquiries) Melanie Toyne-Sewell / Katie Duffell Tel: +44 20 7457 2020 Email: VarmX@instinctif.com

Another opportunity to meet the VarmX team and get more insight into our programs.

Come meet the VarmX team at BioEquity Europe in San Sebastián, Spain.

Meet the VarmX team The VarmX team will be attending the #LSXWorld Congress (29-30 April) and #BioEquityEurope (12-14 May).   At the LSX World Congress, we look to engage and interact with investors and other innovative #biopharmaceutical companies. @Martijn Negen, our SVP Global Commercial Strategy & Business Development, is on a panel discussing: Empowering Emerging Biotechs: Enhancing the Path to Commercialisation.   At Bio€quity Europe, we will present a company update and engage with participants to explore strategic collaborations and potential investments.   If you are interested in meeting our team or getting further information, please contact: info@varmx.com.   #anticoagulation #innovation   @LSX - partnering for Life Science eXecutives @BioCentury Inc.

Meet the VarmX team The VarmX team will be attending the #LSXWorld Congress (29-30 April) and #BioEquityEurope (12-14 May).   At the LSX World Congress, we look to engage and interact with investors and other innovative #biopharmaceutical companies. @Martijn Negen, our SVP Global Commercial Strategy & Business Development, is on a panel discussing: Empowering Emerging Biotechs: Enhancing the Path to Commercialisation.   At Bio€quity Europe, we will present a company update and engage with participants to explore strategic collaborations and potential investments.   If you are interested in meeting our team or getting further information, please contact: info@varmx.com.   #anticoagulation #innovation   @LSX - partnering for Life Science eXecutives @BioCentury Inc.

Process Engineer at VarmX   VarmX is a clinical-stage Leiden based biotech company that is focusing on the development of therapies in the field of hemostasis and thrombosis. Originally a spin-off from the Leiden University Medical Center (LUMC), our mission is to develop and manufacture therapeutic proteins to restore hemostasis. Our lead compound, VMX-C001, is intended to safely and effectively restore hemostasis in case of bleeding or emergency surgery in patients taking so-called oral factor Xa inhibitors. The process to produce GMP-grade VMX-C001 has been developed and scaled-up at our production sites in Denmark and Germany. However, the process may be further optimized by making incremental changes or by changing cell line and / or production mode.    VarmX is currently looking for a Process Engineer to spearhead process development activities at our new lab facility on the Leiden Bioscience park. Within this role, the Process Engineer (full-time) will be responsible for setting up the process development lab, for the development of mammalian suspension cell cultures and for protein production in bioreactors. In addition, the candidate will be responsible for upstream process characterization, cell line development and project management. The candidate will be actively involved in day-to-day CMC activities and will also support downstream process characterization and drug production in collaboration with the scientific team. Required qualifications This position is open for university (MSc) graduates with 5+ years of working experience in life sciences or biochemical engineering, or PhD graduates with equivalent training and experience. The candidate should have a proven track record in process development using mammalian cell lines, should be comfortable working in a small team and must have excellent oral and writing skills in English. Additionally, the candidate should be willing to travel to our collaborators in Denmark and Germany a few times a year. Relevant experience with bioreactors and in process characterization is mandatory. More experienced candidates will be considered for a more senior position.   Offer We offer you a highly dynamic job in an interesting and developing company environment. You will be working at our state-of-the-art laboratory and office building Plus Ultra in Leiden and in collaboration with external VarmX team members in Denmark. VarmX offers full-time employment, competitive salary, 25 holidays, contribution to pension, travel reimbursement and ample training opportunities.   Please apply as soon as possible if you are interested in this position by sending your CV and motivation letter to the address below.   Contact Viola Strijbis Email: v.strijbis@varmx.com Company info: www.varmx.com  

Great opportunity to join a great team with a promising portfolio.